All News

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

Two people have transformed my journey from pain into possibility. In their presence, I find the strength to continue. Together, they've taught me that even in collapse and ill health, life can bloom again.

Providing patient-centered education and navigation support significantly increases consent rates for genomic testing, making testing integration feasible.

A U.S. phase 1 trial of Alveltamig opened at UK Markey, where the first patient with small cell lung cancer was treated in late October.

Dr. Elena Elimova discussed data showing 21-month progression-free survival with Ziihera, Tevimbra and chemotherapy for some patients.

Kyle Donahue, who enrolled in a clinical trial at Brigham and Women's Hospital, is now a five-year survivor of brain cancer.

The American Cancer Society’s 2026 Cancer Statistics report shows the five-year survival rate for all cancers has reached a record high of 70%.

Now that I have been living with my chronic cancer for 16 and a half years, I’ve been reflecting on how my attitude has changed over time.

Nutritional support helps malnourished patients with advanced gastric cancer maintain chemotherapy and may extend time to treatment failure.

Dr. Benjamin Jon Golas explains that surgery, chemotherapy and radiation form the foundation of curative-intent treatment for patients with pancreas cancer.

CURE sat down with Dr. E. Antonio Chiocca to discuss a new brain cancer treatment being studied in an ongoing clinical trial.

Dr. Nadine A. Jackson explains how relatively simple interventions may help close gaps in access to genomics-driven trials across gastrointestinal cancers.

Dr. Ian Flinn explains how subcutaneous Lunsumio VELO uses bispecific antibodies for quick, durable treatment in relapsed/refractory follicular lymphoma.

I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

Updated data from GOBLET Cohort 4 demonstrated activity with Reolysin plus Tecentriq in patients with third-line metastatic squamous cell anal carcinoma.

Dr. Ian Flinn explains how Lunsumio VELO works, offering an outpatient immunotherapy option with accelerated FDA approval.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

After Donna Rigby visited the emergency department at Hackensack Meridian Jersey Shore University Medical Center, tests showed stage 2 lung cancer.

The U.S. FDA has accepted a supplemental application for Besremi in adults with essential thrombocythemia with an Aug. 30, 2026 action date.

I share how choosing what to do with my hair during treatment helped me reclaim control and redefine empowerment.

Receiving a diagnosis of stage 1 clear cell renal cell carcinoma can be a shock, but this is the most common and most treatable stage of kidney cancer

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

I am profoundly, fiercely grateful for every day beyond that harrowing diagnosis. But gratitude is not silence, and survival is not a finish line.

Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.

Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained.

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

The FDA granted fast track designation to Enolen for patients with low-to-intermediate risk prostate cancer.